A large study of androgen receptor germline variants and their relation to sex hormone levels and prostate cancer risk. Results from the National Cancer Institute Breast and Prostate Cancer Cohort Consortium.
BACKGROUND: Androgens are key regulators of prostate gland maintenance and prostate cancer growth, and androgen deprivation therapy has been the mainstay of treatment for advanced prostate cancer for many years. A long-standing hypothesis has been that inherited variation in the androgen receptor (A...
Main Authors: | Lindström, S, Ma, J, Altshuler, D, Giovannucci, E, Riboli, E, Albanes, D, Allen, N, Berndt, S, Boeing, H, Bueno-de-Mesquita, H, Chanock, S, Dunning, A, Feigelson, H, Gaziano, J, Haiman, C, Hayes, R, Henderson, B, Hunter, D, Kaaks, R, Kolonel, L, Le Marchand, L, Martínez, C, Overvad, K, Siddiq, A, Stampfer, M |
---|---|
Format: | Journal article |
Language: | English |
Published: |
2010
|
Similar Items
-
CYP19A1 genetic variation in relation to prostate cancer risk and circulating sex hormone concentrations in men from the Breast and Prostate Cancer Cohort Consortium.
by: Travis, R, et al.
Published: (2009) -
Association of type 2 diabetes susceptibility variants with advanced prostate cancer risk in the Breast and Prostate Cancer Cohort Consortium.
by: Machiela, M, et al.
Published: (2012) -
Sequence variants of estrogen receptor beta and risk of prostate cancer in the National Cancer Institute Breast and Prostate Cancer Cohort Consortium.
by: Chen, Y, et al.
Published: (2007) -
A Genome-wide Pleiotropy Scan for Prostate Cancer Risk.
by: Panagiotou, O, et al.
Published: (2015) -
Pooled analysis of phosphatidylinositol 3-kinase pathway variants and risk of prostate cancer.
by: Koutros, S, et al.
Published: (2010)